Update on recent molecular and genetic advances in frontotemporal lobar degeneration

34Citations
Citations of this article
31Readers
Mendeley users who have this article in their library.

Abstract

Great strides have been made in the last 2 years in the field of frontotemporal lobar degeneration (FTLD), particularly with respect to the genetics and molecular biology of FTLD with ubiquitinated inclusions. It is now clear that most cases of familial FTLD with ubiquitinated inclusions have mutations in the progranulin gene, located on chromosome 17. It is also clear that most ubiquitinated inclusions in FTLD with ubiquitinated inclusions are composed primarily of TAR DNA-binding protein-43. Thus, FTLDs can be separated into 2 major groups (i.e. tauopathies and ubiquitinopathies), and most of the ubiquitinopathies can now be defined as TAR DNA-binding protein-43 proteinopathies. Many of the familial FTLDs are linked to chromosome 17, including both the familial tauopathies and the familial TAR DNA-binding protein-43 proteinopathies with progranulin mutations. This review highlights the neuropathologic features and the most important discoveries of the last 2 years and places these findings into the historical context of FTLD. © 2008 by the American Association of Neuropathologists, Inc.

Cite

CITATION STYLE

APA

Bigio, E. H. (2008, July). Update on recent molecular and genetic advances in frontotemporal lobar degeneration. Journal of Neuropathology and Experimental Neurology. https://doi.org/10.1097/NEN.0b013e31817d751c

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free